Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study

详细信息    查看全文

• 作者：Melisa L. Wong^a ; ^{melisa.wong@ucsf.edu} ; Timothy L. McMurry^b ; ^{tlm6w@eservices.virginia.edu} ; George J. Stukenborg^b ; ^{gjs6r@eservices.virginia.edu} ; Amanda B. Francescatti^c ; ^{afrancescatti@facs.org} ; Carla Amato-Martz^d ; ^{cmartz@alliancefoundationtrials.org} ; Jessica R. Schumacher^e ; ^{schumacher@surgery.wisc.edu} ; George J. Chang^f ; ^{GChang@mdanderson.org} ; Caprice C. Greenberg^e ; ^{greenberg@surgery.wisc.edu} ; David P. Winchester^g ; ^{DWinchester@facs.org} ; Daniel P. McKellar^h ; ^{d.mckellar1958@gmail.com} ; Louise C. Walterⁱ ; ^{Louise.Walter@ucsf.edu} ; Benjamin D. Kozower^j ; ^{kozowerb@wudosis.wustl.edu}
• 关键词：Non-small cell lung cancer ; Recurrence ; Treatment ; Geriatric oncology
• 刊名：Lung Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：102
• 期：Complete
• 页码：108-117
• 全文大小：1612 K
• 卷排序：102

文摘

33.8% of stage I–III NSCLC patients developed postoperative recurrence at 5 years. 79.5% of patients with locoregional recurrence received active cancer treatment. 77.3% of patients with distant recurrence received active cancer treatment. Older patients, independent of comorbidity, were less likely to receive treatment. Women and those with substance abuse were also less likely to receive treatment.